

14 February 2020



**Notification of  
Final Purchase Price for the share buy back**

**Heidelberg, Germany, and Cambridge, UK, 14 February 2020** - As part of the share buyback offer directed at the acquisition of own shares and published on 24 January 2020 on the website of 4basebio AG at [www.investors.4basebio.com](http://www.investors.4basebio.com) and announced in the Federal Gazette (*Bundesanzeiger*), 5,584,558 shares within the price range of EUR 1.60 to EUR 1.85 have been tendered to 4basebio AG by the end of the acceptance period on 10 February 2020 (12.00 noon, local time Frankfurt am Main). In accordance with the offer as of 24 January 2020 and the volume increase decided by the Management Board on 10 February 2020, the offer of 4basebio AG related to a buyback of up to 5,230,726 shares in total ("**Target Number of Shares**").

As the total number of shares for which the offer was accepted by the shareholders is higher than the Target Number of Shares, the Final purchase price pursuant to Section 2.2 b) i) of the offer document corresponds to the lowest price within the Purchase Price Range (i.e. EUR 1.60 to EUR 1.85) at which the Company can acquire the Target Number of Shares on the basis of the declared Acceptances. The Final purchase Price determined by the Company on this basis at the end of the period is EUR 1,85 per share. The allocation quota is currently being determined and will be announced separately without delay.

The settlement of the offer is expected to take place on 24 February 2020.

Heidelberg, 14 February 2020  
4basebio AG  
The Management Board

**About 4basebio AG: [www.4basebio.com](http://www.4basebio.com)**

4basebio AG, formerly operating under the name of Expedeon AG, is an enabler of exciting advances in medical science and patient care. After divestment of its immunology and proteomics products portfolio on January 1 2020, the Company changed its name to 4basebio AG reflecting the enhanced focus on technologies and products centered around DNA. The Company will focus on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines. Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.

4basebio AG has offices in Germany, Spain, UK, and the US. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).

**For further information, please contact:**

**4basebio AG**

Dr. Heikki Lanckriet

CEO/CSO

Phone: +44 1223 873 364

Email: [heikki.lanckriet@4basebio.com](mailto:heikki.lanckriet@4basebio.com)

Investors' information: [investors.4basebio.com](http://investors.4basebio.com)

**MC Services AG (Investor Relations and International Media Relations)**

Julia Hofmann

Phone: +49 89 210228 0

Email: [4basebio@mc-services.eu](mailto:4basebio@mc-services.eu)

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###